Cytogam® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) is indicated in the United States for the prophylaxis of cytomegalovirus (CMV) disease associated with transplantation of kidney, lung, liver, pancreas, and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.1
Cytogam is a hyperimmune product that contains antibodies speciﬁc for the cytomegalovirus.1
Cytogam is available in a 50 mL single-dose vial (50 mg/mL) and can be obtained through most specialty distributors.1
On August 6, 2019 Saol Therapeutics purchased Cytogam (Cytomegalovirus Immune Globulin Intravenous [Human]) from CSL Behring. Product labeling and packaging will continue to reﬂect the CSL Behring name until the labeling transition activities are completed for commercially distributed products.
Phone Number: 833-779-2614